DMARDs

DMARDs

Disease-modifying anti-rheumatic drugs, drugs used mainly in the treatment of RHEUMATOID ARTHRITIS. They act in various ways to relieve the severity of the condition.

Disease Modifying Anti-Rheumatic Drugs (DMARDs)

A class of antirheumatic drugs, including chloroquine, methotrexate, cyclosporine, and gold compounds, that influence the disease process itself and do not only treat its symptoms.
Mentioned in: Antirheumatic Drugs

disease-modifying antirheumatic drugs

; DMARDs group of cytokine-inhibiting agents, used singly or in combination, to minimize and/or control inflammation, joint swelling and tissue destruction characteristic of rheumatoid disease, reducing incidence of irreversible joint damage; e.g. penicillamine, gold salts, antimalarials (chloroquine and hydroxychloroquine), drugs affecting the immune response (azathioprine, methotrexate and enteracept), sulfasalazine and corticosteroids
References in periodicals archive ?
Patients who received methotrexate in combination with other disease-modifying antirheumatic drugs were significantly more likely to remain on anti-tumor necrosis factor therapy than were those who received methotrexate monotherapy or other DMARDs without methotrexate, in a study of more than 10,000 patients in the British Society for Rheumatology Biologies Register.
Early therapy with combinations of conventional DMARDs has been shown to retard the radiologic progression of RA for a period of up to 5 years, but until now the effects of initial aggressive DMARD therapy on radiologic prognosis after that were unknown.
Sustained remission, defined as the absence of synovitis for longer than 1 year without the use of DMARDs, was achieved by 69 of these patients (15%) with an average follow-up of 8 years.
DMARDs, such as methotrexate and sulfasalazine, are indicated for all patients with rheumatoid arthritis and are the first line of defense against the disease.
The findings also reveal that the launch and uptake of the novel oral disease-modifying antirheumatic drugs (DMARDs) tofacitinib and the spleen tyrosine kinase (syk) inhibitor fostamatinib disodium, from AstraZeneca and Rigel, will reduce prescribing of non-TNF-alpha inhibitor biologics in the third and fourth lines of treatment in patients who fail conventional DMARDs.
These studies incorporate data from more than 3,300 adults with moderately to severely active RA who have had an inadequate response or intolerance to one or more biologic or non-biologic DMARDs.
These studies included data from more than 3,300 adults with moderately to severely active RA who were found to have had an inadequate response or intolerance to one or more biologic or non-biologic DMARDs.
In a recent study of patients who failed to respond to methotrexate therapy, researchers compared triple therapy--combining the DMARDs sulfasalazine and hydroxychloroquine with methotrexate--and compared it to a combination therapy of the biologic drug etanercept and methotrexate.
This paper will review some of the data that shows CS to be DMARDs and make the argument that they should be part of our treatment paradigm not as an after thought but one of the mainstays.
5 per cent of patients on DMARDs developed dementia - compared with three per cent of those who did not.
5% of patients on DMARDs developed dementia, compared with 3% of those not taking the drugs.